Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Expands Study Sites For Seclidemstat Dose Expansion Trial

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) has announced the addition of Fox Chase Cancer Center in Philadelphia, Pennsylvania, as an active study site for the ongoing clinical trial dose-expansion phase. The company evaluates its flagship candidate, seclidemstat, to treat patients with advanced FET-rearranged and refractory or relapsed Ewing sarcomas. 

Salarius to evaluate seclidemstat in Ewing sarcoma 

Fox Chase’s addition expands the participating active trial site number to nine for the open-label study seeking to evaluate recommended seclidemstat phase 2 dose. Patient enrolment is underway at the site, with the first subjects in the dose-expansion phase of the study dosed already.  Seclidemstat is a proprietary oral, lysine-specific histone demethylase (1 LSD1) reversible inhibitor. LSD1 is an enzyme that has been demonstrated to be vital in the progression and advancement of various cancers.

According to the amended protocol, the dose-expansion study will now include three arms, with the first arm recruiting 30 Ewing sarcoma patients to investigate seclidemstat combination with cyclophosphamide and topotecan. The company believes that the data released at the ASCO 2021 showed synergy when the combination was used in Ewing Sarcoma. The second arm will study seclidemstat as a single agent in 15 myxoid liposarcoma patients. Finally, the third arm investigates seclidemstat on 15 patients having selected sarcomas sharing similar biology to Ewing sarcoma. 

Fox Chase delighted to work with Salarius to study Sclidemstat

Cancer Epigentics Institute, Fox Chase Cancer Centre director Jonathan Whetstine said, “We are excited to be working with Salarius and look forward to exploring the potential of seclidemstat and its ability to inhibit the LSD1 enzyme. Based on our extensive research into the epigenetic causes of cancer, we believe LSD1 inhibition holds great promise in the treatment of many cancers. We believe data from preclinical studies using Ewing sarcoma cell lines has demonstrated the molecule’s ability to hit two aspects of the enzyme simultaneously.”